ReviewSeminars in oncology2011
Metabolic tumor imaging using magnetic resonance spectroscopy.
Review in Seminars in oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Neurochemical changes in patients with chronic low back pain detected by proton magnetic resonance spectroscopy: A systematic review.NeuroImage. Clinical · 2017Pooled it
- Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?Diagnostic and interventional radiology (Ankara, Turkey)Pooled it
- Double DANTE-PRESS: Development of a 1H-MRS Multifrequency-Selective Sequence for Simultaneous In Vivo Quantification of Glutathione and Glutamate at 7 Tesla.NMR in biomedicine · 2026Article
- Review
- Chemical exchange saturation transfer imaging and diffusion weighted imaging for colon 26 tumor bearing mice.Scientific reports · 2025Article
- Optical imaging provides flow-cytometry-like single-cell level analysis of HIF-1Biophotonics discovery · 2025Article
- Point-of-care optical spectroscopy platform and ratio-metric algorithms for rapid and systematic functional characterization of biological modelsJournal of biomedical optics · 2024Article
- Harnessing THz Technology: Biosensor for Highly Accurate Cervical Cancer Cell Detection via Refractive Index.Cell biochemistry and biophysics · 2024Article
- Development and Enhancement of PCF-based Sensors for Terahertz-frequency Region Breast Cancer Cell Detection.Cell biochemistry and biophysics · 2024Article
- Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases.Medicina (Kaunas, Lithuania) · 2024Article
- Bench to Bedside Development of [Molecules (Basel, Switzerland) · 2023Review
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- Evolving Diagnostic and Treatment Strategies for Pediatric CNS Tumors: The Impact of Lipid Metabolism.Biomedicines · 2023Review
- Article
- Choline metabolism and its implications in cancer.Frontiers in oncology · 2023Review
- Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- [ACS omega · 2022Article
- Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells.Frontiers in immunology · 2022Review
- Metabolomics in cancer research and emerging applications in clinical oncology.CA: a cancer journal for clinicians · 2021Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The adaptability and the genomic plasticity of cancer cells, and the interaction between the tumor microenvironment and co-opted stromal cells, coupled with the ability of cancer cells to colonize distant organs, contribute to the frequent intractability of cancer. It is becoming increasingly evident that personalized molecular targeting is necessary for the successful treatment of this multifaceted and complex disease. Noninvasive imaging modalities such as magnetic resonance (MR), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are filling several important niches in this era of targeted molecular medicine, in applications that span from bench to bedside. In this review we focus on noninvasive magnetic resonance spectroscopy (MRS) and spectroscopic imaging (MRSI) and their roles in future personalized medicine in cancer. Diagnosis, the identification of the most effective treatment, monitoring treatment delivery, and response to treatment are some of the broad areas into which MRS techniques can be integrated to improve treatment outcomes. The development of novel probes for molecular imaging--in combination with a slew of functional imaging capabilities--makes MRS techniques, especially in combination with other imaging modalities, valuable in cancer drug discovery and basic cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.